BrainsWay featured in USA Today America250 segment on neuromodulation

BrainsWay said it was featured in a USA Today America250 segment about how neuromodulation and neuroscience are reshaping mental health care. The segment highlights Deep TMS as a non-drug treatment option for depression, OCD and smoking addiction as treatment-resistant depression remains a major unmet need.

Why it matters: - The segment puts BrainsWay and Deep TMS in front of a broad audience at a moment when mental health care is moving toward more personalized, non-drug treatment options. - The company is tying its technology to a larger clinical debate: how brain-network-based medicine could expand options for people who do not respond to standard medication. - The release cites an estimated 30% of people with depression who do not adequately respond to at least two antidepressants, underscoring the scale of treatment-resistant depression.

What happened: - BrainsWay Ltd. said it participated in USA Today’s America250 segment, The Network Within: Rethinking How Brain Disorders Are Treated. - The segment focuses on advances in neuroscience and neuromodulation and their role in the future of mental health care. - The program includes BrainsWay’s Deep Transcranial Magnetic Stimulation technology, or Deep TMS, as an example of a noninvasive treatment approach. - Featured participants include Dr. Colleen Hanlon, vice president of medical affairs at BrainsWay; Dr. Owen Muir, chief medical officer at Radial and NeuroLief; and Deep TMS patient General Ferg Foley, a U.S. military veteran.

The details: - Deep TMS is designed to help treat depression, anxious depression, obsessive-compulsive disorder and smoking addiction. - The company says Deep TMS uses patented H-Coil technology designed to stimulate deeper and broader neural networks than first-generation TMS systems. - The segment discusses neuroplasticity, or the brain’s ability to adapt and form new neural connections. - Hanlon said the future of mental health care lies in better understanding and targeting the brain networks associated with mental health disorders. - Hanlon added that the segment reflects a broader conversation in health care about innovation, neuroplasticity and expanding access to non-drug treatment options. - Foley said he tried multiple medications without relief and viewed Deep TMS as a new option after running out of alternatives. - Foley said the treatment could matter for first responders and veterans facing mental health challenges. - The release says the film highlights how innovative mental health treatments can affect daily life, recovery and long-term wellbeing.

Between the lines: - BrainsWay is using the America250 platform to frame Deep TMS as part of a wider shift in psychiatry away from medication-only care. - The focus on veterans and first responders suggests the company is emphasizing populations that may be more visibly affected by treatment-resistant conditions. - The message is as much about clinical momentum as it is about public awareness and adoption.

What's next: - BrainsWay says additional clinical trials of Deep TMS are underway in psychiatric, neurological and addiction disorders. - The company said it will continue working to increase global awareness of and access to Deep TMS. - The America250 series will continue spotlighting organizations that are shaping the future through science, technology and innovation.

The bottom line: - BrainsWay is positioning Deep TMS as a scalable, evidence-based option in a growing market for noninvasive mental health treatments. - The USA Today feature gives that pitch a mainstream media platform as demand for alternatives to medication remains high.